chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Musculoskeletal stiffness, Pain in extremity, SARS-CoV-2 test
Clinical narrative: After nearly two months both arms stillhurt when I wake up at night or in the morning; The stiffness wears off after the pill and during the day, and returns at night.; This is a spontaneous report from a contactable consumer, the patient. A 77-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration in the left arm on an unknown date in Jan2021 at 08:15 (at the age of 77-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9264) via an unspecified route of administration in the right arm on 06Feb2021 at 08:15 (at the age of 77-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to bee sting. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take any concomitant medication. The patient previously received varicella zoster vaccine (MANUFACTURER UNKNOWN) for immunisation on unknown date and experienced allergy to vaccine. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On an unknown date in Jan2021 at 12:00, the experienced pain in arm and stiffness. After nearly two months both arms still hurt when patient wake up at night or in the morning and patient has taken naproxen sodium (ALEVE) to take away the pain. The stiffness wears off after the pill and during the day and returns at night. Both pains started after getting the vaccinations. The patient had the second shot in right arm because didn't want to double up any pain the left arm. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of events and included treatment with chiropractic medicine, heat pad and massage machine. Since the vaccination, the patient had tested for COVID-19. On 19Jan2021, the patient underwent COVID-19 virus test via nasal swab and the result was negative. The clinical outcome of the events pain in arm and stiffness was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Gait disturbance, Hypertension, Insomnia, Night sweats
Clinical narrative: Excruciating pain beginning in feet and legs, spreading throughout entire body.; Excruciating pain beginning in feet and legs, spreading throughout entire body.; Difficulty walking; Extreme exhaustion; Difficulty sleeping; Occasional high blood pressure; Profuse sweating during sleep; This is a spontaneous report from a contactable consumer. A 68-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EML201) via an unspecified route of administration in the left arm on 25Feb2021 at 13:00 (at the age of 68-year-old), as a single dose for COVID-19 immunisation. Medical history included atherosclerosis and stent placement. The patient was not aware of any allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included pravastatin (MANUFACTURER UNKNOWN), carvedilol (COREG) and clopidogrel bisulfate (PLAVIX); all taken for unspecified indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 04Mar2021 at 12:00, the patient experienced excruciating pain beginning in feet and legs and on same day patient experienced pain spreading throughout entire body, had difficulty walking, felt extreme exhaustion, and difficulty sleeping. The patient had occasional high blood pressure, profuse sweating during sleep. The patient had ongoing and constant pain for a week currently at the time of this report and reported that vitals otherwise were normal. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events excruciating pain beginning in feet and legs, spreading throughout entire body, difficulty walking, extreme exhaustion, difficulty sleeping, occasional high blood pressure, profuse sweating during sleep was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Pain, Pain in extremity
Clinical narrative: Excruciating pain beginning in feet and legs, spreading throughout entire body.; Excruciating pain beginning in feet and legs, spreading throughout entire body.; Difficulty walking; Extreme exhaustion; Difficulty sleeping; Occasional high blood pressure; Profuse sweating during sleep; This is a spontaneous report from a contactable consumer. A 68-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EML201) via an unspecified route of administration in the left arm on 25Feb2021 at 13:00 (at the age of 68-year-old), as a single dose for COVID-19 immunisation. Medical history included atherosclerosis and stent placement. The patient was not aware of any allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included pravastatin (MANUFACTURER UNKNOWN), carvedilol (COREG) and clopidogrel bisulfate (PLAVIX); all taken for unspecified indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 04Mar2021 at 12:00, the patient experienced excruciating pain beginning in feet and legs and on same day patient experienced pain spreading throughout entire body, had difficulty walking, felt extreme exhaustion, and difficulty sleeping. The patient had occasional high blood pressure, profuse sweating during sleep. The patient had ongoing and constant pain for a week currently at the time of this report and reported that vitals otherwise were normal. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events excruciating pain beginning in feet and legs, spreading throughout entire body, difficulty walking, extreme exhaustion, difficulty sleeping, occasional high blood pressure, profuse sweating during sleep was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Hypersomnia, Micturition disorder, Urine flow decreased
Clinical narrative: Mild headache; Extra daytime sleepiness; Fatigue; Problems urinating; Problems urinating (very slow, could not exert pressure to normal levels); This is a spontaneous report from a contactable consumer, the patient. A 73-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the left arm on 08Mar2021 at 11:15 (at the age of 73-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, high blood pressure, breast cancer survivor and Fuch's corneal dystrophy. The patient was allergic to rubber/latex and cannot tolerate statins or hormone blockers. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included losartan (MANUFACTURER UNKNOWN), chlortalidone (CHLORTHALIDONE), potassium chloride (KLOR-CON), acetylsalicylic acid (ASPIRIN) and metformin (MANUFACTURER UNKNOWN), all taken for an unspecified indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Mar2021 at 11:15, the patient experienced mild headache, extra daytime sleepiness, fatigue and problems urinating (very slow, could not exert pressure to normal levels). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events mild headache, extra daytime sleepiness, fatigue. and problems urinating (very slow, could not exert pressure to normal levels) were recovering at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Malaise, Nausea, Vertigo, Vomiting
Clinical narrative: About one day after the shot, I experienced a dull headache that has lasted almost one week; Nausea; Feeling unwell; On the 6th day after the shot, I experienced severe vertigo and several bouts of vomiting; On the 6th day after the shot, I experienced severe vertigo and several bouts of vomiting; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 05Mar2021 at 09:45 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and allergies (unspecified). Allergies to medications, food, and other products was reported as not to my knowledge. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. On 06Mar2021 at 16:00, about one day after the shot the patient experienced a dull headache that lasted almost one week, nausea, and feeling unwell. On an unknown date in Mar2021, on the 6th day after the shot, the patient experienced severe vertigo and several bouts of vomiting. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event dull headache that lasted almost one week was recovered on an unknown date in Mar2021. The clinical outcome of the events nausea, feeling unwell, severe vertigo and several bouts of vomiting was recovering at the time of this report.   No follow-up attempts are required, information about lot/batch number cannot be obtained. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Constant headaches; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 05Feb2021 at 16:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in left arm on 01Mar2021 at 16:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 and sulfonamide allergy. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications included calcium (MANUFACTURER UNKNOWN), daily vitamin (MANUFACTURER UNKNOWN) and pravastatin (MANUFACTURER UNKNOWN); all from an unknown start date, for an unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Feb2021 the patient experienced constant headaches usually in one spot in the back of head on left side, started after first dose about 5 days after vaccination. No therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event constant headaches usually in one spot in the back of head on left side was not recovered at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Nausea
Clinical narrative: Headaches; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the left arm on 05Mar2021 at 13:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included alopecia. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included fluoxetine (MANUFACTURER UNKNOWN) from unknown date for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received miconazole nitrate (MONISTAT 1) and experienced drug allergy. On 05Mar2021 at 18:30, the patient experienced headache and nausea. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headaches and nausea was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle twitching
Clinical narrative: Random eye twitches in the right eye; This is a spontaneous report from a non-contactable consumer, the patient. A 28-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the right arm on 11Mar2021 at 11:45 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Medical history included lyme disease and allergic to mushrooms. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included unspecified birth control (MANUFACTURER UNKNOWN) and loratadine/pseudoephedrine sulfate (CLARITIN-D) both for an unknown indication from an unknown date and unknown if ongoing. On 11Mar2021 at 12:15, the patient experienced random eye twitches in the right eye. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event random eye twitches in the right eye was not recovered at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Arm soreness at injection site area; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: E13247) via an unspecified route of administration in the left arm on 11Mar2021 at 10:15 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included elevated cholesterol and PSA (psoriatic arthritis). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the vaccination. Concomitant medications included rosuvastatin calcium (CRESTOR), omega-3-acid ethyl ester (LOVAZA), minerals nos/vitamins nos (CENTRUM), ubidecarenone (COQ10), magnesium sulfate (MANUFACTURER UNKNOWN) and ergocalciferol (VIT D); all for an unknown indication from an unknown date and unknown if ongoing. The patient previously received amoxicillin (MANUFACTURER UNKNOWN), for unknown indication on an unknown date and experienced drug allergy. On 11Mar2021 at 15:00, the patient experienced arm soreness at injection site area, increased in intensity, peaking between 12-24 hours post injection and then began to decrease in intensity. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the reported events. The clinical outcome of the event arm soreness at injection site area was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Conjunctivitis
Clinical narrative: The physician has prescribed meds to treat these symptoms, giving me a diagnosis of conjunctivitis; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 06Mar2021 at 10:45 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. Medical history included hyperlipidemia, osteopenia, arthritis, pre-diabetic. The patient was allergic to pork, dust and mold. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), simvastatin (MANUFACTURER UNKNOWN), pantoprazole (MANUFACTURER UNKNOWN) and vitamins(MANUFACTURER UNKNOWN); all taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously took pethidine hydrochloride (DEMEROL) for an unknown indication on an unknown date and experienced drug allergy. On 06Mar2021 at 21:30, the patient experienced skin irritation around eyelid of right eye, commencing about 12 hours post injection. The irritation progressively increased and then went to a lesser degree to left eye. After patient's efforts to treat it with OTC items, it failed to help, six days post vaccination. The patient received prescribed medications by the doctor to treat these symptoms and was diagnosed of conjunctivitis on 12Mar2021. As per physician's advice, the patient had urged to see an ophthalmologist, which patient will do Monday. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with hydroxyzine (MANUFACTURER UNKNOWN), prednisone (MANUFACTURER UNKNOWN) and mometasone (MANUFACTURER UNKNOWN). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events eyelid irritation and conjunctivitis were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Arm started to ache; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the left arm on 11Mar2021 at 14:00 (at the age of 73-years-old) as a single dose for COVID-19 immunisation. Medical history included allergic reactions to tomatoes, shellfish and some nuts. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medication within two weeks prior to the vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Mar2021 at 14:00, within an hour or so from the time of injection, the patients arm started to ache and it felt like he had been punched several times by a boxer. Last night when he rolled over in bed it woke him up. Throughout the day it had gotten a little better but was still troubling. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the event arm started to ache was recovered with sequelae at unknown date at 2021.   No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Vaccination site pain
Clinical narrative: I have had a headache after the second shot on March 01st; A few days after, The site were I had the vaccine is still very sort touch. That was 10 days ago; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 01Mar2021 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included dementia early on-set. The patient had no known allergies to medications, food or other products. Prior to the vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included escitalopram oxalate (LEXAPRO), memantine (MANUFACTURER UNKNOWN) and rosuvastatin (MANUFACTURER UNKNOWN); all for unspecified indication from unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06Feb2021 at 16:00 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. On 01Mar2021 at 16:00, the patient experienced headache after the second shot. On an unknown date in Mar2021, a few days after the site where patient had the vaccine was still very sort touch, that was 10 days ago. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event headache and site where patient had the vaccine was still very sort touch was not recovered at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Headache
Clinical narrative: Dizziness; Headache; This is a spontaneous report from a contactable consumer, the patient. A 72-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 10Mar2021 at 15:30 (at the age of 72-years-old) as a single dose for COVID-19 immunisation. Medical history included heart disease and diabetes. Prior to vaccination, the patient was not diagnosed with COVID -19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included metformin hydrochloride (GLUCOPHAGE), escitalopram (ESCITALOPRAM), acetylsalicylic acid (ASPIRIN) and clopidogrel bisulfate (PLAVIX) all from an unknown date for an unknown indication and unknown if ongoing. The patient previously received carisoprodol (SOMA) and experienced drug allergy.  On 10Mar2021 at 23:00, the patient experienced dizziness and headache. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events dizziness and headache were not recovered at the time of this report. No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site rash
Clinical narrative: Severe, elevated rash at vaccination site; This is a spontaneous report from a contactable consumer, the patient. A 74-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: CN5318) via an unspecified route of administration in the left arm on 26Feb2021 at 14:15 (at the age of 74-years-old) as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes, high blood pressure and slow thyroid. The patient has no known allergies to medications, food, or other products (also reported as not that known of). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included metformin (MANUFACTURER UNKNOWN), levothyroxine sodium (SYNTHROID), enalapril maleate (MANUFACTURER UNKNOWN) and rosuvastatin calcium (ROSUVAST); all for unknown indications from unknown date and unknown if ongoing. On 01Mar2021 at 09:00, the patient experienced severe, elevated rash presented 3 days after vaccination on her left arm at vaccination site. It was also reported that, as of 12Mar2021 (14 days after shot) it was still there. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event severe, elevated rash at vaccination site was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Left arm became very sore; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 02Mar2021 at 07:00 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID -19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included ezetimibe (MANUFACTURER UNKNOWN), lisinopril (MANUFACTURER UNKNOWN), metformin (MANUFACTURER UNKNOWN), allopurinol (MANUFACTURER UNKNOWN) and Escitalopram (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown date and unknown if ongoing. On 04Mar2021 at 15:00, two days after the vaccination, the patient experienced left arm became very sore. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the event left arm became very sore was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Heart rate, Heart rate increased
Clinical narrative: Within a couple of minutes experienced some dizziness; followed with a rapid heartbeat for about a minute. Pulse rate was approximately 120 bpm.; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6204) via an unspecified route of administration in the right arm on 12Mar2021 at 10:15 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high and cholesterol high. The patient had known allergies to medications, food or other products (unspecified). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received other medications (unspecified) within two weeks prior to the vaccination. On 12Mar2021 at 10:15, within a couple of minutes the patient experienced some dizziness and then followed with a rapid heartbeat for about a minute. Pulse rate was approximately 120 bpm. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event dizziness and heart rate increased was recovered on an unknown date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Dry mouth, Palpitations, Paraesthesia oral
Clinical narrative: After 2 minutes of the shot ," I "started feeling dizzy, dry mouth, tingling on my lips and palpitations for about 3-4 minutes; After 2 minutes of the shot , I started feeling dizzy, dry mouth, tingling on my lips and palpitations for about 3-4 minutes; After 2 minutes of the shot , I started feeling dizzy, dry mouth, tingling on my lips and palpitations for about 3-4 minutes; After 2 minutes of the shot , I started feeling dizzy, dry mouth, tingling on my lips and palpitations for about 3-4 minutes; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: en6202) via an unspecified route of administration in the right arm on 10Mar2021 at 15:30 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included palpitations. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Mar2021 at 15:32, after 2 minutes of the shot, the patient started feeling dizzy, dry mouth, tingling on her lips and palpitations for about 3-4 minutes. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events feeling dizzy, dry mouth, tingling on lips and palpitations were recovered on 10Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Confusional state, Disorientation, Dizziness, Fatigue
Clinical narrative: Significantly Dizzy; Confusion/disorientation; Confusion/disorientation; Headache; Nausea; Stomach ache; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198, expiration date: Jun2021) via an unspecified route of administration in the left arm on 10Mar2021 at 09:15 (at the age of 73-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, vitiligo, arthritis, migraines, hypothyroid, high cholesterol, reflux, IBC (Inflammatory breast cancer), penicillin allergy, sulfonamide allergy, shellfish allergy, and drug allergy (statins). Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included LEVOTHYROXINE; VERAPAMIL; FAMOTIDINE; VITAMIN D AND ASA, all for an unknown indication from an unknown date and unknown if ongoing. The patient previously took LEVOFLOXACIN, CODEINE, and NITROFURANTOIN, all for unknown indications, on unknown dates and experienced drug allergy. On 10Mar2021 at 10:00, the patient experienced significantly dizzy, confusion/disorientation, headache, nausea, stomach ache, and fatigue. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events significantly dizzy, confusion/disorientation, headache, nausea, stomach ache, and fatigue was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Nausea
Clinical narrative: Significantly Dizzy; Confusion/disorientation; Confusion/disorientation; Headache; Nausea; Stomach ache; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198, expiration date: Jun2021) via an unspecified route of administration in the left arm on 10Mar2021 at 09:15 (at the age of 73-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, vitiligo, arthritis, migraines, hypothyroid, high cholesterol, reflux, IBC (Inflammatory breast cancer), penicillin allergy, sulfonamide allergy, shellfish allergy, and drug allergy (statins). Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included LEVOTHYROXINE; VERAPAMIL; FAMOTIDINE; VITAMIN D AND ASA, all for an unknown indication from an unknown date and unknown if ongoing. The patient previously took LEVOFLOXACIN, CODEINE, and NITROFURANTOIN, all for unknown indications, on unknown dates and experienced drug allergy. On 10Mar2021 at 10:00, the patient experienced significantly dizzy, confusion/disorientation, headache, nausea, stomach ache, and fatigue. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events significantly dizzy, confusion/disorientation, headache, nausea, stomach ache, and fatigue was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Arm soreness; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 05Mar2021 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension, diabetes and depression. The patient had no known allergies to medications, food, or other products. The patient received unspecified concomitant medications. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM9809) via an unspecified route of administration on the left arm on 12Feb2021 at 12:45 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. On 05Mar2021 at 14:00, the patient experienced arm soreness. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event arm soreness was resolved on an unknown date in Mar2021.    No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Nausea, SARS-CoV-2 test
Clinical narrative: I have been nauseated; Had headaches off and on; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the left arm on 09Mar2021 at 16:15 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not take any concomitant medications. On 10Mar2021 at 04:00, the patient experienced have been nauseated, had headaches off and on and fatigue. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. On an unknown date, the patient underwent nasal swab (SARS-CoV-2 test) and the result was negative. The clinical outcome of the events have been nauseated, had headaches off and on and fatigue was recovering at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site induration, Vaccination site swelling, Vaccination site warmth
Clinical narrative: Hardening in area of injection with swelling, redness and emitted heat.; Hardening in area of injection with swelling, redness and emitted heat.; Hardening in area of injection with swelling, redness and emitted heat.; Hardening in area of injection with swelling, redness and emitted heat.; This is a spontaneous report from a contactable consumer, the patient. A 71-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318, expiration date: 31May2021) via an unspecified route of administration in the arm left on 08Mar2021 at 00:00 (at the age of 71-year-old) as a single dose for COVID-19 immunisation. Medical history included heart disorder, myelodysplasia, soy allergy, contrast media allergy (contrast dye), allergic reaction to antibiotic (synthetic antibiotics) and drug allergy (statin drugs). Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3246, expiration date: 30Apr2021) via an unspecified route of administration in the arm left on 15Feb2021 at 12:00 (at the age of 71-year-old) as a single dose for COVID-19 immunisation. On 08Mar2021 at 12:30, after the second dose of vaccination, the patient experienced a hardening in area of injection with swelling, redness and emitted heat. It was also reported that side effects persisted even at the time of this report (12Mar2021). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event vaccination site induration, vaccination site swelling, vaccination site erythema and vaccination site warmth was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Feeling abnormal
Clinical narrative: Brain fog. Starting from the afternoon of the first day, but primarily from 24hrs - 60 hrs post vax (still ongoing).  I cannot complete complex multistep tasks in some instances; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200) via an unspecified route of administration in the left arm on 10Mar2021 at 09:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included attention deficit-hyperactivity disorder (ADHD) and mixed anxiety/depression. The patient had no known allergies to medications, food or other products. Prior to vaccination, the patient was not diagnosed with COVID -19. Concomitant medications included MMJ, diphenhydramine hydrochloride (BENADRYL), allopurinol (ALOPURINOL) and amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL); all from an unknown date for an unknown indication and was unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On 12Mar2021, the patient experienced brain fog. Starting from the afternoon of the first day, but primarily from 24hours - 60 hours post vax (still ongoing). He cannot complete complex multistep tasks in some instances, but not all. For instance, organizing files in a directory leaves him lost or with numerous errors. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event brain fog. Starting from the afternoon of the first day, but primarily from 24hours - 60 hours post vax (still ongoing). cannot complete complex multistep tasks in some instances but not all was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling hot, Pain
Clinical narrative: Felt achy morning after; A little warm but no fever; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 8N6208) via an unspecified route of administration in the left arm on 03Mar2021 at 11:45 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications was not reported. On an unknown date in Mar2021, the patient felt achy morning after and a little warm but had no fever. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events felt achy morning after and a little warm but had no fever was unknown at the time of the report.   No follow-up attempts are possible. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Nausea, Nervousness
Clinical narrative: Dizziness/ light-headed; Feeling shaky; Nauseated; This is a spontaneous report from a contactable other healthcare professional. A 44-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9266) via intramuscular route of administration on 12Feb2021 at 14:30 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included migraine and known allergies to shellfish. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. It was unknown whether the patient received any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included nortriptyline (MANUFACTURER UNKNOWN) and sumatriptan (MANUFACTURER UNKNOWN); both for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. On 12Feb2021 at 14:30, post vaccination approximately 20 minutes, the patient experienced dizziness, feeling shaky, nauseated, and light headed. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of events dizziness/ light-headed, feeling shaky and nauseated was recovered on an unknown date in 2021.  No follow-up attempts are possible. No further information is expected.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pruritus
Clinical narrative: Periodic Itching at injection site 10 days post vaccination; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the left arm on 28Feb2021 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. On 10Mar2021, 10 days after vaccination, the patient experienced periodic itching at injection site. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event periodic itching at injection site 10 days post vaccination was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness
Clinical narrative: Intermittent dizziness; This is a spontaneous report from a contactable consumer, the patient. A 74-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318) via an unspecified route of administration in the left arm on 16Feb2021 at 14:00 (at the age of 74-years-old) as a single dose for COVID-19 immunisation. The patient did not had any relevant medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received an unspecified medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9261) via an unspecified route of administration in the left arm on 26Jan2021 at 14:00 (at the age of 74-years-old) as a single dose for COVID-19 immunisation. The patient previously received levofloxacin (LEVAQUIN) and experienced drug allergy. On 16Feb2021 at 18:00, the patient experienced intermittent dizziness which began 4 hours after second pfizer vaccine. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event intermittent dizziness was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.